Dennis M. Lanfear
CIK: 0001420822
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Coherus Oncology, Inc.
Discretionary Trading P&L
Holdings
Transaction History (24 total)
- May 29, 2026CHRS
Coherus Oncology, Inc.
Award(A)DirectStock Option (Right to Buy)
402.5K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Award(A)DirectStock Option (Right to Buy)
225K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Award(A)DirectStock Option (Right to Buy)
500K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Award(A)DirectStock Option (Right to Buy)
125K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Award(A)DirectStock Option (Right to Buy)
402.5K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Disposition(D)DirectStock Option (Right to Buy)
200K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Disposition(D)DirectStock Option (Right to Buy)
400K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Disposition(D)DirectStock Option (Right to Buy)
450K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Disposition(D)DirectStock Option (Right to Buy)
500K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Disposition(D)DirectStock Option (Right to Buy)
500K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Disposition(D)DirectStock Option (Right to Buy)
125K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Disposition(D)DirectStock Option (Right to Buy)
402.5K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Disposition(D)DirectStock Option (Right to Buy)
402.5K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Disposition(D)DirectStock Option (Right to Buy)
225K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Award(A)DirectStock Option (Right to Buy)
200K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Award(A)DirectStock Option (Right to Buy)
400K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Award(A)DirectStock Option (Right to Buy)
450K shares- - May 29, 2026CHRS
Coherus Oncology, Inc.
Award(A)DirectStock Option (Right to Buy)
500K shares- - Jan 23, 2026CHRS
Coherus Oncology, Inc.
Award(A)Direct375K shares- - Jan 20, 2026CHRS
Coherus Oncology, Inc.
Tax Payment(F)Direct11.8K shares at avg. $1.55$18K - May 7, 2025CHRS
Coherus BioSciences, Inc.
Award(A)DirectStock Option (Right to Buy)
375K shares- - Jan 20, 2025CHRS
Coherus BioSciences, Inc.
Tax Payment(F)Direct11.8K shares at avg. $1.39$16K - Jan 10, 2025CHRS
Coherus BioSciences, Inc.
Award(A)DirectStock Option (Right to Buy)
575K shares- - Jan 4, 2025CHRS
Coherus BioSciences, Inc.
Tax Payment(F)Direct11.8K shares at avg. $1.66$20K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Award(A) Stock Option (Right to Buy) | 402,500 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Award(A) Stock Option (Right to Buy) | 225,000 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Award(A) Stock Option (Right to Buy) | 500,000 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Award(A) Stock Option (Right to Buy) | 125,000 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Award(A) Stock Option (Right to Buy) | 402,500 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Disposition(D) Stock Option (Right to Buy) | 200,000 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Disposition(D) Stock Option (Right to Buy) | 400,000 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Disposition(D) Stock Option (Right to Buy) | 450,000 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Disposition(D) Stock Option (Right to Buy) | 500,000 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Disposition(D) Stock Option (Right to Buy) | 500,000 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Disposition(D) Stock Option (Right to Buy) | 125,000 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Disposition(D) Stock Option (Right to Buy) | 402,500 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Disposition(D) Stock Option (Right to Buy) | 402,500 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Disposition(D) Stock Option (Right to Buy) | 225,000 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Award(A) Stock Option (Right to Buy) | 200,000 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Award(A) Stock Option (Right to Buy) | 400,000 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Award(A) Stock Option (Right to Buy) | 450,000 | - | - | Direct |
| May 29, 2026 | CHRS Coherus Oncology, Inc. | Award(A) Stock Option (Right to Buy) | 500,000 | - | - | Direct |
| Jan 23, 2026 | CHRS Coherus Oncology, Inc. | Award(A) | 375,000 | - | $0 | Direct |
| Jan 20, 2026 | CHRS Coherus Oncology, Inc. | Tax Payment(F) | 11,839 | $1.55 | $18,350 | Direct |
| May 7, 2025 | CHRS Coherus BioSciences, Inc. | Award(A) Stock Option (Right to Buy) | 375,000 | - | - | Direct |
| Jan 20, 2025 | CHRS Coherus BioSciences, Inc. | Tax Payment(F) | 11,810 | $1.39 | $16,416 | Direct |
| Jan 10, 2025 | CHRS Coherus BioSciences, Inc. | Award(A) Stock Option (Right to Buy) | 575,000 | - | - | Direct |
| Jan 4, 2025 | CHRS Coherus BioSciences, Inc. | Tax Payment(F) | 11,810 | $1.66 | $19,605 | Direct |
1-24 of 24 transactions
About Lanfear Dennis M
Lanfear Dennis M (SEC CIK 0001420822) files insider reports with the SEC as President & CEO of Coherus Oncology, Inc. (CHRS).
Signal8 holds 7 ownership filings by Lanfear Dennis M, all Form 4s, filed between Jan 7, 2025 and Jun 2, 2026. Those filings report 24 transactions, from Jan 4, 2025 to May 29, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Lanfear Dennis M's filings is in REDWOOD CITY, CA.
Recent filings by Lanfear Dennis M
- May 29, 2026: Grants or awards of CHRS derivative securities (5 lines, Form 4, code A).
- May 29, 2026: Disposition to issuer transactions of CHRS derivative securities (9 lines, Form 4, code D).
- May 29, 2026: Grants or awards of CHRS derivative securities (4 lines, Form 4, code A).
- Jan 23, 2026: Grant or award of CHRS shares (Form 4, code A).
- Jan 20, 2026: Tax withholding of CHRS shares (Form 4, code F).
Other insiders filing for Coherus Oncology, Inc. (CHRS)
- Satvat Ali J., Director
- Karachun Rita A, Director
- Newcomer Lee Nisley, Director
- Ryan Michael Lee, Director
- O'Donnell-Tormey Jill, Director
- Wahlstrom Mats, Director